AI assistant
DEXCOM INC — Director's Dealing 2016
Aug 11, 2016
30198_dirs_2016-08-11_682960db-1b8d-4ec7-97f6-79414f0235d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2016-08-09
Reporting Person: SAYER KEVIN R (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-08-09 | Common Stock | M | 20000.0 | $8.79 | Acquired | 362227 | Direct |
| 2016-08-09 | Common Stock | S | 20000.0 | $90.9776 | Disposed | 342227 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-08-09 | Non-Qualified Stock Option (right to buy) | $8.79 | M | 20000.0 | Disposed | 2017-11-06 | Common Stock (20000) | Direct |
Footnotes
F1: This transaction was executed in multiple trades at prices ranging from $90.92 to $91.18. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: Included in this number are 200,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 60,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 50,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017.